Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker IMA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Blue Owl Capital Holdings LP | 1.14M | 9.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Mark N. Lampert | 1.13M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Inc/Il | 1.13M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Partners L P/Il | 1.13M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF GP Holdings LLC | 1.05M | 9.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Partners OS Ltd. | 66,808 | 0.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Biotechnology Value Trading Fund OS LP | 66,808 | 0.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF II GP LLC | 433,269 | 3.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Biotechnology Value Fund II LP | 433,269 | 3.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF I GP LLC | 611,834 | 5.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Biotechnology Value Fund L P | 611,834 | 5.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Mark N. Lampert | 1.11M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Inc/Il | 1.11M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Partners L P/Il | 1.11M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF GP Holdings LLC | 1.03M | 9.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Partners OS Ltd. | 66,808 | 0.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Biotechnology Value Trading Fund OS LP | 66,808 | 0.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF II GP LLC | 433,269 | 3.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Biotechnology Value Fund II LP | 433,269 | 3.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF I GP LLC | 593,189 | 5.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Biotechnology Value Fund L P | 593,189 | 5.3% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Blue Owl Capital Holdings LP | 959,337 | 8.5% | SCHEDULE 13G/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | IMA ImageneBio, Inc. | Orbimed Capital LLC | 135,516 | 1.2% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | IMA ImageneBio, Inc. | OrbiMed Genesis GP LLC | 405,380 | 3.6% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | IMA ImageneBio, Inc. | Orbimed Capital GP VI LLC | 1.09M | 9.6% | SCHEDULE 13D/A ↗ |
| Apr 29, 2026 | SCHEDULE 13D/A (amended) | IMA ImageneBio, Inc. | Orbimed Advisors LLC | 1.50M | 13.1% | SCHEDULE 13D/A ↗ |
| Apr 21, 2026 | SCHEDULE 13G | IMA ImageneBio, Inc. | Ortav Yehudai | 1.18M | 9.9% | SCHEDULE 13G ↗ |
| Apr 21, 2026 | SCHEDULE 13G | IMA ImageneBio, Inc. | Trails Edge Biotechnology Master Fund, LP | 1.18M | 9.9% | SCHEDULE 13G ↗ |
| Apr 21, 2026 | SCHEDULE 13G | IMA ImageneBio, Inc. | Trails Edge Capital Partners, LP | 1.18M | 9.9% | SCHEDULE 13G ↗ |
| Apr 21, 2026 | SCHEDULE 13D | IMA ImageneBio, Inc. | Otello Stampacchia | 936,222 | 8.4% | SCHEDULE 13D ↗ |
| Apr 21, 2026 | SCHEDULE 13D | IMA ImageneBio, Inc. | Claudio Nessi | 935,843 | 8.4% | SCHEDULE 13D ↗ |
| Apr 21, 2026 | SCHEDULE 13D | IMA ImageneBio, Inc. | Omega Fund VI GP Manager, Ltd. | 935,843 | 8.4% | SCHEDULE 13D ↗ |
| Apr 21, 2026 | SCHEDULE 13D | IMA ImageneBio, Inc. | Omega Fund VI GP, L.P. | 935,843 | 8.4% | SCHEDULE 13D ↗ |
| Apr 21, 2026 | SCHEDULE 13D | IMA ImageneBio, Inc. | Omega Fund VI, L.P. | 935,843 | 8.4% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | David Kroin | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Deep Track Capital, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G | IMA ImageneBio, Inc. | Blue Owl Capital Holdings LP | 823,785 | 7.4% | SCHEDULE 13G ↗ |
| Jan 6, 2026 | SCHEDULE 13G | IMA ImageneBio, Inc. | Jacob Ma-Weaver | 643,933 | 5.8% | SCHEDULE 13G ↗ |
| Jan 6, 2026 | SCHEDULE 13G | IMA ImageneBio, Inc. | Cable Car Capital, LP | 643,933 | 5.8% | SCHEDULE 13G ↗ |
| Jan 6, 2026 | SCHEDULE 13G | IMA ImageneBio, Inc. | Funicular Funds, LP | 643,933 | 5.8% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Blue Owl Capital Holdings LP | 540,924 | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Mark N. Lampert | 802,102 | 7.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Inc/Il | 802,102 | 7.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Partners L P/Il | 802,102 | 7.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF GP Holdings LLC | 741,361 | 6.6% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF Partners OS Ltd. | 44,578 | 0.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Biotechnology Value Trading Fund OS LP | 44,578 | 0.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | BVF II GP LLC | 325,596 | 2.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IMA ImageneBio, Inc. | Biotechnology Value Fund II LP | 325,596 | 2.9% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances